文献速递消化系统肿瘤

评估一线S-1联合雷莫西尤单抗治疗老年晚期/复发性胃癌疗效与安全性的II期多中心试验:KSCC1701

A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701.
PubMed 文献 · Eur J Cancer · 2022-03-26

KSCC1701是一项II期多中心试验,纳入48例≥70岁初治晚期/复发性胃癌患者,接受S-1联合雷莫西尤单抗治疗。1年总生存率为65.2%,达到主要终点;中位总生存期16.4个月,中位无进展生存期5.8个月,客观缓解率41.9%。结论认为该方案对老年患者似乎是极佳的治疗选择。

要点

  • ≥70岁初治晚期/复发性胃癌患者接受S-1联合雷莫西尤单抗,1年OS率65.2%,达到预设主要终点。
  • 中位OS 16.4个月,中位PFS 5.8个月,ORR 41.9%。
  • 最常见≥15%的3/4级不良事件为中性粒细胞减少、食欲减退和贫血。

核心结论

  • 作者认为,S-1联合雷莫西尤单抗似乎是老年晚期/复发性胃癌患者的极佳治疗选择。

研究设计与样本

  • II期多中心试验(KSCC1701),纳入化疗初治、年龄≥70岁的晚期/复发性胃癌患者。
  • 患者接受S-1(40-60 mg,每日两次,用药4周,6周为一周期)联合雷莫西尤单抗(8 mg/kg,每2周一次),直至疾病进展。
  • 主要终点为1年总生存率,基于既往S-1方案将预期下限设为40%;次要终点包括无进展生存期、总生存期、客观缓解率和安全性。
  • 2017年9月至2019年11月共入组48例患者(男性34例,女性14例),中位年龄77.5岁,所有患者体能状态为0(n=20)或1(n=28)。

主要发现

  • 1年总生存率为65.2%,达到主要终点。
  • 中位生存时间为16.4个月,中位无进展生存期为5.8个月。
  • 客观缓解率为41.9%。
  • 最常见的3/4级(≥15%)不良事件为中性粒细胞减少、食欲减退和贫血。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The mainstream first-line chemotherapy for advanced/recurrent gastric cancer (ARGC) is combination therapy including platinum-based agents. With the progressive aging of the society, the incidence of gastric cancer in elderly patients is increasing. However, elderly patients cannot tolerate these agents because of renal dysfunction or low quality of life. The KSCC1701 study explored the efficacy and safety of S-1 + ramucirumab in elderly patients with ARGC. PATIENTS AND METHODS: Chemotherapy-naive patients aged ≥70 years with ARGC were eligible. Patients received S-1 (40-60 mg twice daily for 4 weeks in 6-week cycles) and ramucirumab (8 mg/kg every 2 weeks) until disease progression. The primary end-point was the 1-year overall survival (OS) rate. The anticipated lower threshold of 1-year survival was set at 40% in light of previous S-1-based regimens. The secondary end-points included progression-free survival (PFS), OS, the overall response rate (ORR) and safety. RESULTS: Between September 2017 and November 2019, 48 patients (34 men and 14 women) were enrolled in this study. The median patient age was 77.5 years, and all patients had a performance status of 0 (n = 20) or 1 (n = 28). The 1-year OS rate was 65.2%, which met the primary end-point. The median survival time and median PFS were 16.4 and 5.8 months, respectively. The ORR was 41.9%. The most frequent grade 3/4 (≥15%) adverse events were neutropenia, anorexia and anaemia. CONCLUSION: Considering these findings, S-1 + ramucirumab appears to be an excellent treatment option for elderly patients with ARGC. (250 words). This trial has been registered with the Japan Registry of Clinical Trials Registry under the number jRCTs071180066.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kobayshi K, Suyama K, Katsuya H, et al. A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701. Eur J Cancer. 2022. PMID: 35349925. doi:10.1016/j.ejca.2022.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。